Bharat Biotech
-
Decision on Emergency Use Listing of Covaxin likely in August first week: WHO
India | Jul 10, 2021, 04:33 PM ISTSpeaking at a webinar organised by the Centre for Science and Environment (CSE) on Friday, Soumya Swaminathan said the WHO is reviewing Covaxin as its manufacturer Bharat Biotech is now uploading its entire data on the health body’s portal.
-
Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19
India | Jul 03, 2021, 08:37 AM ISTCovaxin gives 77.8 per cent efficacy against COVID 19, and 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant
-
Brazil suspends Bharat Biotech's Covaxin order over graft allegations
India | Jun 30, 2021, 02:12 PM ISTAnnouncing the Brazil government's decision, its Health Ministry said in a statement that "with the recommendation of the Office of the Comptroller General of the Union, the Ministry of Health temporarily suspended the contract for the purchase of Covid-19 vaccine from Covaxin this Tuesday (29)."
-
'Covaxin pricing clearly established': Bharat Biotech clarifies on Brazil deal row
India | Jun 30, 2021, 12:28 PM ISTThe Covaxin contract to Brazil had landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal.
-
Brazil to suspend Covaxin deal with Bharat Biotech over allegations of irregularities by President
World | Jun 30, 2021, 08:21 AM ISTBrazil had in February signed a deal with Bharat Biotech to procure 20 million doses of Covaxin for USD 324 million.
-
Bharat Biotech chairman Krishna Ella given central security cover
India | Jun 29, 2021, 09:03 PM ISTThe officials said Krishna Ella was provided the security cover of Central Industrial Security Force (CISF) armed commandos sometime ago given his current profile of spearheading the production of life-saving vaccines and other medical essentials.
-
Over 1.45 crore vaccine doses available with states: Centre
India | Jun 26, 2021, 11:51 AM ISTMore than 1.45 crore COVID-19 vaccine doses are still available with states and union territories and over 19,10,650 jabs are in the pipeline.
-
Bharat Biotech, WHO meet for 'pre-submission' of Covaxin's Emergency Use Listing
India | Jun 24, 2021, 12:11 PM ISTAs per WHO guidelines, Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies. It has already submitted 90 per cent of documents to WHO for obtaining EUL for Covaxin
-
Covaxin shows 77.8% efficacy in phase 3 trial, likely to get clearance today
India | Jun 22, 2021, 05:52 PM ISTHyderabad-based Bharat Biotech has been facing tough questions over the delay in announcing its phase 3 trial data of the vaccine.
-
Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Sources
India | Jun 22, 2021, 09:32 AM ISTBharat Biotech's Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.
-
Bharat Biotech's pre-submission meeting for Covaxin EUL with WHO on June 23
India | Jun 18, 2021, 03:45 PM ISTBharat Biotech had said last month that it expects approval for its COVID-19 vaccine Covaxin from the World Health Organisation for Emergency Use Listing (EUL) during July-September.
-
Aaj Ki Baat: Why rumour was spread on social media that calf serum was used in making of Covaxin vaccine
Aaj Ki Baat | Jun 16, 2021, 10:48 PM ISTThe Union Health Ministry has said that some social media posts have distorted facts that the indigenously manufactured Covaxine contains the serum of a newborn calf. The Health Ministry said that the serum of the newborn calf is used only for the preparation and development of Vero cells
-
Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech
India | Jun 15, 2021, 03:24 PM ISTThe supply price of Bharat Biotech''s COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.
-
AIIMS Delhi to start Covaxin trial for children aged 6-12 from today
India | Jun 15, 2021, 08:35 AM ISTThe recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today.
-
Covaxin's phase 3 results soons, says Bharat Biotech
India | Jun 13, 2021, 09:11 AM ISTBharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent.
-
Covaxin manufacturer Bharat Biotech to carry out clinical trials in US
India | Jun 12, 2021, 05:30 PM ISTIn a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation.
-
Covaxin phase 3 full trial data to be made public in July: Bharat Biotech
India | Jun 09, 2021, 06:48 PM ISTCovaxin phase 3 full trial results will be made public in July, Bharat Biotech informed on Wendesday. Covaxin is one of the three vaccines other than Oxford's Covishield and Russia's Sputnik V, that are being administered in India.
-
Covaxin protects against Delta, Beta variants of COVID-19, says study
India | Jun 09, 2021, 01:26 PM ISTThe Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country, the Beta variant (B.1.351) was first discovered in South Africa.
-
Vaccination in Rajasthan halted since May 31: State Health Minister
News | Jun 08, 2021, 08:29 PM ISTRajasthan Health Minister Dr Raghu Sharma informed that vaccination in the state has been halted since May 31. He further said that next batch of vaccines will arrive on June 09.
-
Delhi: AIIMS to start screening children for Covaxin trials from today
India | Jun 07, 2021, 09:33 AM ISTAIIMS in Delhi will begin screening of children aged 2 to 18 years for Covaxin trials from today.